OS05.6 Final risk model for Temozolomide (TMZ)-Myelotoxicity in patients with Glioblastoma treated on NRG Oncology’s RTOG 0825

le Armstrong, T. S., Gilbert, M. R., Bondy, M., Sulman, E., Yuan, Y., Zhou, R., Vera, E., Wendland, M., Pugh, S., Scheurer, M.
Foilsithe in Neuro Oncol (2017)

A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3.

le White, P S, Maris, J M, Beltinger, C, Sulman, E, Marshall, H N, Fujimori, M, Kaufman, B A, Biegel, J A, Allen, C, Hilliard, C
Foilsithe 1995

HIGH-THROUGHPUT SCREENING OF GLIOMA STEM CELL LINES FOR DRUG STRUCTURE- AND GENOTYPE-CORRELATED SENSITIVITY TO A PANEL OF TYROSINE KINASE INHIBITORS

le de Groot, John, Thomas, C., Piao, Y., Nguyen, N., Drewry, D., Zuercher, B., Verhaak, R., Stephan, C., Sulman, E.P., Lang, F., Yung, A.
Foilsithe 2014